{"product_id":"iccc-vrio-analysis","title":"ImmuCell Corporation (ICCC): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to ImmuCell Corporation (ICCC)'s market position as we dissect its core capabilities through the rigorous VRIO lens. This analysis distills whether its current assets truly deliver sustainable competitive advantage by examining their Value, Rarity, Inimitability, and Organization. Dive in now to see the definitive verdict on what makes ImmuCell Corporation (ICCC) uniquely powerful - or potentially vulnerable - in today's landscape.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmuCell Corporation (ICCC) - VRIO Analysis: First Core Capabilities \/ Resources: First Defense® Established Product Franchise \u0026amp; Market Penetration\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at a core asset for ImmuCell Corporation (ICCC) in the First Defense® franchise, which is their established product line providing immediate immunity for newborn calves. The key takeaway here is that this franchise is a proven revenue driver, but its competitive edge needs constant defense against market shifts.\u003c\/p\u003e\n\n\u003cp\u003eThe financial performance for the twelve months ending September 30, 2025, shows this franchise is performing well, bringing in approximately \u003cstrong\u003e$27.8 million\u003c\/strong\u003e in product sales. This is a solid chunk of the estimated \u003cstrong\u003e$81.8 million\u003c\/strong\u003e domestic calf scours market opportunity, meaning there’s still plenty of room to run, but it also shows significant existing penetration.\u003c\/p\u003e\n\n\u003ch3\u003eVRIO Assessment of First Defense® Franchise\u003c\/h3\u003e\n\u003cp\u003eHere’s the quick math on how this resource stacks up using the VRIO framework. Honestly, it’s a strong foundation, but not an impenetrable fortress.\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Dimension\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eImplication\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eScore (1-4)\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eProvides immediate, proven revenue of \u003cstrong\u003e$27.8 million\u003c\/strong\u003e (12 months ending 9\/30\/2025) against an \u003cstrong\u003e$81.8 million\u003c\/strong\u003e market.\u003c\/td\u003e\n    \u003ctd\u003eMeets customer needs (scours prevention) and generates cash.\u003c\/td\u003e\n    \u003ctd\u003e4\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eModerately rare; established, proven biologicals for immediate immunity in this niche are not common.\u003c\/td\u003e\n    \u003ctd\u003eGives a temporary advantage over competitors lacking this specific, proven mechanism.\u003c\/td\u003e\n    \u003ctd\u003e3\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eDifficult due to established distribution and customer reliance on the Immediate Immunity™ benefit.\u003c\/td\u003e\n    \u003ctd\u003eTime and relationships make it costly and slow for a new entrant to replicate fully.\u003c\/td\u003e\n    \u003ctd\u003e2\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eHigh; the company is focused on growing sales and transitioning from backlog to new business opportunities.\u003c\/td\u003e\n    \u003ctd\u003eManagement is aligned to exploit this resource now that supply constraints are eased.\u003c\/td\u003e\n    \u003ctd\u003e4\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Implications and Actionable Insights\u003c\/h3\u003e\n\u003cp\u003eThe current competitive advantage is assessed as temporary. While the product has strong efficacy and distribution, the market is still subject to new competitive entries or shifts in farming practices, so you can’t rest on your laurels. The company has recently recovered from supply issues, with an estimated annual capacity of about \u003cstrong\u003e$30 million\u003c\/strong\u003e for this line, which is a defintely positive sign for capturing near-term demand.\u003c\/p\u003e\n\u003cp\u003eThe high Organization score is key right now. With the backlog cleared, management can focus resources:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDrive adoption in remaining market segments.\u003c\/li\u003e\n\u003cli\u003eReinforce distributor relationships with reliable supply.\u003c\/li\u003e\n\u003cli\u003eLeverage testimonials showing scours dropping by 75% in some trials.\u003c\/li\u003e\n\u003cli\u003eMaximize sales before a competitor launches a comparable product.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmuCell Corporation (ICCC) - VRIO Analysis: Second Core Capabilities \/ Resources: Re-Tain® Late-Stage Novel Product Pipeline\n\u003c\/h2\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Real-Life Data\/Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh Potential\u003c\/td\u003e\n\u003ctd\u003eAddresses an estimated \u003cstrong\u003e$2 billion\u003c\/strong\u003e annual economic harm from subclinical mastitis in the U.S. dairy industry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eNovel, bacteriocin-based treatment with \u003cstrong\u003eno FDA-required milk discard\u003c\/strong\u003e or pre-slaughter withdrawal label restrictions.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eVery Difficult\u003c\/td\u003e\n\u003ctd\u003eRequires significant prior investment, including approximately \u003cstrong\u003e$25.2 million\u003c\/strong\u003e invested in development through 2022 and construction of the Drug Substance facility for approximately \u003cstrong\u003e$20.8 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\/Active\u003c\/td\u003e\n\u003ctd\u003eInitiated Investigational Product use in \u003cstrong\u003e2025\u003c\/strong\u003e to collect field performance data through the remainder of \u003cstrong\u003e2025\u003c\/strong\u003e and into \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained (Contingent)\u003c\/td\u003e\n\u003ctd\u003eLonger-term goal is to exceed \u003cstrong\u003e$35 million\u003c\/strong\u003e of annual total product sales within five years post-launch.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe Re-Tain® late-stage novel product pipeline represents a resource with high potential value by targeting the estimated \u003cstrong\u003e$2 billion\u003c\/strong\u003e annual economic harm caused by subclinical mastitis in the U.S. dairy industry.\u003c\/p\u003e\n\n\u003cp\u003eThe rarity is supported by its unique profile as a novel treatment alternative to traditional antibiotics, specifically lacking \u003cstrong\u003eFDA-required milk discard\u003c\/strong\u003e or pre-slaughter withdrawal claims.\u003c\/p\u003e\n\n\u003cp\u003eReplication difficulty is high, evidenced by the substantial sunk costs and time invested in its development, including approximately \u003cstrong\u003e$25.2 million\u003c\/strong\u003e invested through \u003cstrong\u003eDecember 31, 2022\u003c\/strong\u003e, in development efforts.\u003c\/p\u003e\n\n\u003cp\u003eOrganizational readiness is currently in an active testing phase, with the company implementing a strategy to test market acceptance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInvestigational Product use commenced in \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eData collection on product performance is planned over the remainder of \u003cstrong\u003e2025\u003c\/strong\u003e and into \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company made its Non-Administrative New Animal Drug Application (NADA) submission in early \u003cstrong\u003eJanuary of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinancial performance context from the existing product line shows significant growth leading up to potential Re-Tain® launch:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProduct sales for the twelve-month period ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e, were approximately \u003cstrong\u003e$28.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross margin for the three-month period ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e, reached \u003cstrong\u003e44%\u003c\/strong\u003e of sales.\u003c\/li\u003e\n\u003cli\u003eNet income was approximately \u003cstrong\u003e$502,000\u003c\/strong\u003e for the three-month period ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIf approved, the anticipated competitive advantage is contingent upon capturing market share, with the company's longer-term goal set to exceed \u003cstrong\u003e$35 million\u003c\/strong\u003e in annual total product sales in the five-year period following Re-Tain® market launch.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmuCell Corporation (ICCC) - VRIO Analysis: Third Core Capabilities \/ Resources: Proprietary Manufacturing \u0026amp; Scalability Investment\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for meeting current demand and positions the company for future growth, with capacity planned to exceed \u003cstrong\u003e$40 million\u003c\/strong\u003e annually. The company is currently evaluating incremental investments to increase capacity by an additional \u003cstrong\u003e33%\u003c\/strong\u003e to approximately \u003cstrong\u003e$40 million\u003c\/strong\u003e or more annually.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; in-house formulation and aseptic filling capabilities are less common than relying solely on contract manufacturers. The company paused a \u003cstrong\u003e$4-million\u003c\/strong\u003e investment to bring Re-Tain formulation and aseptic filling in-house.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; the physical facility, process refinement, and accumulated operational knowledge are not easily copied. The company began a series of investments during \u003cstrong\u003e2019\u003c\/strong\u003e to increase its production capacity to over \u003cstrong\u003e$30 million\u003c\/strong\u003e per year.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management has demonstrated commitment by investing capital to increase capacity and eliminate the prior backlog. The company has shown commitment by:\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eAchieving production output that annualized to approximately \u003cstrong\u003e$26.8 million\u003c\/strong\u003e in Q4 2023.\u003c\/li\u003e\n\u003cli\u003eReducing the order backlog to under \u003cstrong\u003e$100,000\u003c\/strong\u003e as of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e, from approximately \u003cstrong\u003e$3.4 million\u003c\/strong\u003e as of \u003cstrong\u003eMay 6, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTargeting a gross margin of \u003cstrong\u003e40%\u003c\/strong\u003e guidance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; while the recent expansion helps, the physical asset base can eventually be matched by well-funded rivals. Gross margin increased to \u003cstrong\u003e43%\u003c\/strong\u003e in Q3 2025 compared to \u003cstrong\u003e26%\u003c\/strong\u003e in Q3 2024.\u003c\/p\u003e\n\n\u003cp\u003eKey Manufacturing and Backlog Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue \/ Date\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Annualized Capacity Goal\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$30 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSet as a goal during \u003cstrong\u003e2023\u003c\/strong\u003e and \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTargeted Incremental Capacity\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$40 million\u003c\/strong\u003e or more\u003c\/td\u003e\n\u003ctd\u003eEvaluation for incremental investment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBacklog as of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUnder \u003cstrong\u003e$100,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSignificant reduction from prior periods.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBacklog as of \u003cstrong\u003eMarch 31, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$9.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePrior to significant backlog depletion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity Utilization (FY24 H1 Avg)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGuidance for remainder of year was \u003cstrong\u003e95%\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to \u003cstrong\u003e26%\u003c\/strong\u003e in Q3 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmuCell Corporation (ICCC) - VRIO Analysis: Fourth Core Capabilities \/ Resources: High Gross Margin Profile (Post-Contamination Recovery)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Drives profitability and cash generation.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGross margin as a percentage of product sales achieved \u003cstrong\u003e42.6%\u003c\/strong\u003e for the nine-month period ended September 30, 2025, compared to \u003cstrong\u003e27.3%\u003c\/strong\u003e for the comparable nine-month period in 2024. The net income for the nine-month period ended September 30, 2025, was \u003cstrong\u003e$1.8 million\u003c\/strong\u003e, a swing of \u003cstrong\u003e$4.5 million\u003c\/strong\u003e over the net loss of \u003cstrong\u003e($2.7 million)\u003c\/strong\u003e in the same period last year.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod Ended September 30, 2025\u003c\/td\u003e\n\u003ctd\u003ePeriod Ended September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNine-Month Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e42.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThree-Month Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNine-Month Product Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(Implied lower)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Rare; achieving such a sharp margin recovery suggests deep process optimization.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Difficult; the margin improvement is tied to process efficiency and yield gains from overcoming contamination.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: High; the team executed on cost of goods sold reduction and inventory management to realize this gain.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProduct sales for the nine-month period ended September 30, 2025, increased by \u003cstrong\u003e7%\u003c\/strong\u003e or \u003cstrong\u003e$1.3 million\u003c\/strong\u003e over the nine-month period ended September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eThe financial improvement was driven by higher product sales at a significantly higher gross margin, coupled with operating expense control, mainly in the form of reduced product development expenses related to Re-Tain®.\u003c\/li\u003e\n\u003cli\u003eThe Company has overcome a prolonged order backlog situation that arose from previous interruptions in production.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; improved operational efficiency embedded in the process should maintain higher margins going forward.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmuCell Corporation (ICCC) - VRIO Analysis: Fifth Core Capabilities \/ Resources: Intellectual Property Portfolio (Patents\/Trade Secrets)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Protects the core technology behind First Defense® and the novel mechanism of Re-Tain®, securing future revenue streams.\u003c\/p\u003e\n\u003cp\u003eThe value is substantiated by the significant market size addressed by the products:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Company estimates the cost of scours in the US, which First Defense® addresses, to be over $700 million per year.\u003c\/li\u003e\n\u003cli\u003eMastitis infections result in approximately $2 BILLION in economic losses to the U.S. dairy industry annually, the market targeted by Re-Tain®.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\/Metric\u003c\/th\u003e\n\u003cth\u003eAssociated Product\u003c\/th\u003e\n\u003cth\u003eFinancial\/Statistical Figure\u003c\/th\u003e\n\u003cth\u003eReference Period\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Annual Market Loss\u003c\/td\u003e\n\u003ctd\u003eScours (First Defense® target)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$700 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUS Market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Annual Market Loss\u003c\/td\u003e\n\u003ctd\u003eSubclinical Mastitis (Re-Tain® target)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$2 BILLION\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eU.S. Dairy Industry Annually\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative Direct Development Cost\u003c\/td\u003e\n\u003ctd\u003eRe-Tain®\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$30.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2000 to 2024 (excluding certain costs)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest Twelve-Month Product Sales\u003c\/td\u003e\n\u003ctd\u003eFirst Defense® (Primary Driver)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$27.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eEnded September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStated Sales Goal\u003c\/td\u003e\n\u003ctd\u003eCombined Products\u003c\/td\u003e\n\u003ctd\u003eExceed \u003cstrong\u003e$35 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBy approximately 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpensed Product Development Cost\u003c\/td\u003e\n\u003ctd\u003eRe-Tain® Focus\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ending March 28, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; many in the sector have IP, but the specific, proven applications are unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Difficult; trade secrets related to manufacturing yields and formulation are protected by secrecy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Moderate; the company recognizes the need for expenditure to protect this asset, indicating organizational focus.\u003c\/p\u003e\n\u003cp\u003eAll product development expenses are expensed as incurred, as are all related patent costs.\u003c\/p\u003e\n\u003cp\u003eThe company has made significant investments:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAggregate direct expenditure for Re-Tain® development between 2000 and 2024 was approximately \u003cstrong\u003e$30.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAn investment of approximately \u003cstrong\u003e$4 million\u003c\/strong\u003e was planned to replace a CMO and bring formulation and aseptic filling for Re-Tain® in-house, though this has been paused.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial performance metrics related to product realization:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross margin improved to \u003cstrong\u003e30%\u003c\/strong\u003e of sales for the year ending March 28, 2025, up from \u003cstrong\u003e22%\u003c\/strong\u003e the prior year.\u003c\/li\u003e\n\u003cli\u003eGross margin reached \u003cstrong\u003e44%\u003c\/strong\u003e for the three-month period ended June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained; strong patent protection, if in place, provides a legal barrier to entry.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmuCell Corporation (ICCC) - VRIO Analysis: Sixth Core Capabilities \/ Resources: Customer Trust and Antibiotic Reduction Alignment\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eCreates a loyal customer base that values the product’s role in reducing antibiotic use in the food supply chain, a national imperative.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Company estimates the cost of scours in the US to be over \u003cstrong\u003e$700 million\u003c\/strong\u003e per year.\u003c\/li\u003e\n\u003cli\u003eMastitis infections result in approximately \u003cstrong\u003e$2 BILLION\u003c\/strong\u003e in economic losses to the U.S. dairy industry annually.\u003c\/li\u003e\n\u003cli\u003eRe-Tain®, a product candidate, provides an alternative to traditional antibiotics with zero milk discard and zero meat withhold claims in the U.S.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eRare; deep, long-standing trust in a specific farm-gate product is hard-earned over years of consistent performance.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod Ending June 30, 2025\u003c\/th\u003e\n\u003cth\u003ePeriod Ending September 30, 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Sales Growth (12-Month)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrder Backlog\u003c\/td\u003e\n\u003ctd\u003eUnder \u003cstrong\u003e$100,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A (Operating from a clean slate)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eVery difficult; trust is built through years of reliable results, not just marketing spend.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Company has completed investments to increase production capacity for the First Defense® product line to over \u003cstrong\u003e$30 million\u003c\/strong\u003e in annual sales value.\u003c\/li\u003e\n\u003cli\u003eThe Company is evaluating incremental investments to increase capacity by an additional \u003cstrong\u003e33%\u003c\/strong\u003e to approximately \u003cstrong\u003e$40 million\u003c\/strong\u003e or more.\u003c\/li\u003e\n\u003cli\u003eThe longer-term goal is to exceed \u003cstrong\u003e$35 million\u003c\/strong\u003e in product sales by approximately \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; the company's stated purpose is centered on improving health and productivity while reducing antibiotics.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eQ1 2025\u003c\/th\u003e\n\u003cth\u003eNine Months Ended Sept 30, 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Sales\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$8.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$20.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\/(Loss)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.8 million\u003c\/strong\u003e (vs. net loss of \u003cstrong\u003e$2.7 million\u003c\/strong\u003e in prior year)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin Percentage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e42%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e42.6%\u003c\/strong\u003e (vs. \u003cstrong\u003e27.3%\u003c\/strong\u003e in prior year period)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained; this alignment with broader industry and public health goals creates a strong moat.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProduct sales increased by \u003cstrong\u003e52%\u003c\/strong\u003e to \u003cstrong\u003e$26.5 million\u003c\/strong\u003e for the full year ended December 31, 2024, compared to \u003cstrong\u003e$17.5 million\u003c\/strong\u003e in 2023.\u003c\/li\u003e\n\u003cli\u003eThe Company's annualized production output was approximately \u003cstrong\u003e103%\u003c\/strong\u003e of its estimated full capacity as of year-end 2024.\u003c\/li\u003e\n\u003cli\u003eThe order backlog was reduced from approximately \u003cstrong\u003e$9.4 million\u003c\/strong\u003e a year earlier to approximately \u003cstrong\u003e$4.4 million\u003c\/strong\u003e as of January 1, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmuCell Corporation (ICCC) - VRIO Analysis: Seventh Core Capabilities \/ Resources: Strengthened Balance Sheet and Debt Structure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides financial flexibility to fund operations and development without immediate external pressure; net working capital was \u003cstrong\u003e$12.8 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; the recent debt refinancing at a fixed \u003cstrong\u003e6.5%\u003c\/strong\u003e rate extending terms through the third quarter of \u003cstrong\u003e2030\u003c\/strong\u003e is a specific, positive financial achievement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; refinancing is possible, but achieving favorable terms depends on current performance and lender confidence.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management executed strategic refinancing and cost control to fortify cash reserves; cash and cash equivalents were approximately \u003cstrong\u003e$3.9 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; financial strength is always relative and can erode if performance falters or debt terms mature unfavorably later.\u003c\/p\u003e\n\u003cp\u003eKey financial metrics supporting the strengthened balance sheet:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet working capital increased to approximately \u003cstrong\u003e$12.8 million\u003c\/strong\u003e as of September 30, 2025, from \u003cstrong\u003e$10.6 million\u003c\/strong\u003e as of December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents increased to approximately \u003cstrong\u003e$3.9 million\u003c\/strong\u003e as of September 30, 2025, from \u003cstrong\u003e$3.8 million\u003c\/strong\u003e as of December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eNine-month net income for the period ended September 30, 2025, was \u003cstrong\u003e$1,809,000\u003c\/strong\u003e, compared to a net loss of \u003cstrong\u003e($2,671,000)\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eGross margin as a percentage of product sales improved to \u003cstrong\u003e43%\u003c\/strong\u003e for the nine months ended September 30, 2025, from \u003cstrong\u003e27%\u003c\/strong\u003e for the comparable period in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe debt refinancing details illustrate the shift in debt structure:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt Component\u003c\/td\u003e\n\u003ctd\u003ePrior Interest Rate(s)\u003c\/td\u003e\n\u003ctd\u003eNew Interest Rate\u003c\/td\u003e\n\u003ctd\u003eNew Maturity\/Term End\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRefinanced Loans Total Principal\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7%\u003c\/strong\u003e and \u003cstrong\u003e8%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFixed \u003cstrong\u003e6.5%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAmortization through Q3 \u003cstrong\u003e2030\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Balloon Payments Avoided\u003c\/td\u003e\n\u003ctd\u003eAggregating approximately \u003cstrong\u003e$1,946,000\u003c\/strong\u003e due Q3 \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmuCell Corporation (ICCC) - VRIO Analysis: Eighth Core Capabilities \/ Resources: Internal Regulatory Submission Expertise (NADA Process)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Essential for bringing Re-Tain® to market; demonstrated by the submission of the NADA's CMC Technical Section in \u003cstrong\u003eearly January 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; specialized experience in the FDA's New Animal Drug Application (NADA) pathway for biologics is specialized.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Difficult; the institutional knowledge of navigating specific regulatory hurdles is not easily transferred.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Moderate; the process is ongoing, but the company has successfully cleared several submission milestones.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; expertise is only valuable until the key approval (Re-Tain®) is secured, after which the advantage shifts to the product itself.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eNADA Submission Component\u003c\/th\u003e\n\u003cth\u003eSubmission Date\/Period\u003c\/th\u003e\n\u003cth\u003eStatus\/Milestone\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMC Technical Section (First Phased Submission)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 28, 2019\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst of five major Technical Sections submitted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman Food Safety Technical Section\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ3 2018\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrevious Technical Section Complete Letter received.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMC Technical Section (Third Submission)\u003c\/td\u003e\n\u003ctd\u003ePrior to \u003cstrong\u003eMay 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReceived Technical Section Incomplete Letter.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMC Technical Section (Fourth Submission) \u0026amp; Non-Administrative NADA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEarly January of 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSubmission made after clearing prior observations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe regulatory and market context involves the following specific figures:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe mastitis market addressed by Re-Tain® represents an estimated \u003cstrong\u003e$2 billion\u003c\/strong\u003e annual economic harm to the dairy industry.\u003c\/li\u003e\n\u003cli\u003eThe statutory review period for the Non-Administrative NADA submission is up to \u003cstrong\u003e180 days\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe goal of the combined filing was to eliminate an additional \u003cstrong\u003e60-day\u003c\/strong\u003e review period associated with an Administrative NADA submission.\u003c\/li\u003e\n\u003cli\u003eThe company has completed investments to increase its production capacity for the First Defense® product line to over \u003cstrong\u003e$30 million\u003c\/strong\u003e in annual sales value, with an estimated current annual capacity of \u003cstrong\u003e$30M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company had previously received \u003cstrong\u003efour\u003c\/strong\u003e Technical Section Complete Letters from the FDA prior to the 2025 submission.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmuCell Corporation (ICCC) - VRIO Analysis: Ninth Core Capabilities \/ Resources: Operational Resilience and Backlog Elimination\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Restored confidence in the supply chain, allowing the company to operate from a 'clean slate' and focus on growth. This is evidenced by meeting current customer demand and rebuilding inventory.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; successfully recovering from contamination events that caused significant backlogs (down from approximately \u003cstrong\u003e\\$3.4 million\u003c\/strong\u003e as of May 6, 2025, to under \\$100,000 by June 30, 2025) is a major feat.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; resilience is built through crisis management and process hardening, which is experiential learning. The cost of scrapped work-in-process and finished goods due to contamination in the first half of 2025 was \u003cstrong\u003e\\$208,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the team focused laser-like on quality and product availability across the entire supply chain. The company's cash and cash equivalents increased to approximately \u003cstrong\u003e\\$6.0 million\u003c\/strong\u003e as of June 30, 2025, from \u003cstrong\u003e\\$3.8 million\u003c\/strong\u003e as of December 31, 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; while resilience is proven, the market will test this capability again in the future. The company is now building inventory to meet customer demand going into the peak selling season towards the end of the year and into the first quarter of 2026.\u003c\/p\u003e\n\u003cp\u003eThe operational recovery is reflected in the following comparative financial performance metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod Ended June 30, 2025\u003c\/td\u003e\n\u003ctd\u003ePeriod Ended June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Sales (Three Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$6.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$5.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Sales (Six Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$14.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$12.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Sales (Twelve Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$28.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$23.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (% of Sales) (Six Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e28%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (Six Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNet Loss of \u003cstrong\u003e\\$1.97 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey financial indicators demonstrating the operational turnaround include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProduct sales for the three-month period ended June 30, 2025, increased by \u003cstrong\u003e18%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eGross margin for the three-month period ended June 30, 2025, was \u003cstrong\u003e44%\u003c\/strong\u003e of product sales, compared to \u003cstrong\u003e22%\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eNet income for the three-month period ended June 30, 2025, was approximately \u003cstrong\u003e\\$502,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet working capital increased to approximately \u003cstrong\u003e\\$12.7 million\u003c\/strong\u003e as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eInventory increased to approximately \u003cstrong\u003e\\$8.29 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516184289429,"sku":"iccc-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/iccc-vrio-analysis.png?v=1740183849","url":"https:\/\/dcf-model.com\/fr\/products\/iccc-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}